Clinical Data Arthrosi drug trial in gout delivers for new owner Sobi PharmaphorumSobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.Immunology & InflammationRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) Pharmaphorum Sobi’s $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly’s Verve gambit pays off as base editor cuts cholesterol in early studyNext: Eli Lilly to buy trio of vaccine developers in $3.8bn outlay Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
